文献速递眼底病与葡萄膜炎

5914次玻璃体腔注射ziv-aflibercept的安全性分析

Safety of 5914 intravitreal ziv-aflibercept injections.
PubMed 文献 · Br J Ophthalmol · 2018-08-11

结果显示眼部和全身不良事件均不常见,总体安全性可接受,与其他VEGF抑制类药物相似。

要点

  • 共5914次注射中仅报告1例眼内炎、3例眼内炎症及少量其他眼部不良事件。
  • 全身不良事件包括2例心肌梗死、1例卒中和2例死亡,发生率低。
  • IVZ的眼部和全身安全性与其他VEGF抑制药物相似。

核心结论

  • IVZ具有可接受的眼部和全身安全性,不良事件发生率与其他VEGF抑制药物相似,支持其继续用于多种视网膜疾病。

主要发现

  • 共实施5914次IVZ注射,平均每眼3.73±3.94次,患者平均年龄60.6±12.8岁,涵盖多种脉络膜视网膜病变。
  • 眼部不良事件包括1例眼内炎、3例眼内炎症、1例结膜变薄/坏死和1例巩膜结节。
  • 全身不良事件包括2例心肌梗死、1例卒中和2例死亡。

关键数值与推荐

  • 眼部不良事件:眼内炎1例、眼内炎症3例、结膜变薄/坏死1例、巩膜结节1例。
  • 全身不良事件:心肌梗死2例、卒中1例、死亡2例。

临床怎么用

  • IVZ可用于多种视网膜疾病的玻璃体腔注射治疗,其安全性与其他VEGF抑制药物相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To analyse the pooled safety data of intravitreal ziv-aflibercept (IVZ) therapy for various retinal conditions. METHODS: This was a retrospective, observational study which included patients from 14 participating centres who received IVZ. The medical records of patients who received IVZ from March 2015 through October 2017 were evaluated. Patient demographics and ocular details were compiled. Ocular and systemic adverse events that occurred within 1 month of IVZ injections were recorded and defined as either procedure-related or drug-related. RESULTS: A total of 1704 eyes of 1562 patients received 5914 IVZ injections (mean±SD: 3.73±3.94) during a period of 2.5 years. The age of patients was 60.6±12.8 years (mean±SD) and included diverse chorioretinal pathologies. Both ocular (one case of endophthalmitis, three cases of intraocular inflammation, and one case each of conjunctival thinning/necrosis and scleral nodule) and systemic adverse events (two cases of myocardial infarction, one case of stroke and two deaths) were infrequent. CONCLUSION: This constitutes the largest pooled safety report on IVZ use and includes patients from 14 centres distributed across the globe. It shows that IVZ has an acceptable ocular and systemic safety profile with incidences of adverse events similar to those of other vascular endothelial growth factor inhibitory drugs. The analysis supports the continued use of IVZ in various retinal disorders.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Singh SR, Stewart MW, Chattannavar G, et al. Safety of 5914 intravitreal ziv-aflibercept injections. Br J Ophthalmol. 2018. PMID: 30099379. doi:10.1136/bjophthalmol-2018-312453

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。